Cannovation Clinical Research Partners and Benuvia Announce Strategic Partnership to Deliver Fully Integrated Solutions for Controlled Substance Therapeutics

[Atlanta, GA — Dec 3, 2025] – Cannovation Clinical Research Partners (CCRP), a leading global consultancy specializing in cannabinoid and psychedelic therapeutic development, today announced a strategic partnership with Benuvia Manufacturing, Inc., a U.S.-based DEA-licensed, GMP-certified pharmaceutical manufacturer, to create the industry’s first fully integrated CRO and manufacturing platform for controlled substances.

This alliance unites Cannovation’s expertise in preclinical and clinical research, regulatory strategy, and global commercialization with Benuvia’s end-to-end capabilities in DEA Schedule I–V drug manufacturing, analytical testing, and CMC development. Together, the companies will offer pharmaceutical and biotech sponsors a single, compliant pathway from molecule to market for cannabinoid, psychedelic, and novel CNS therapeutics.

“Together, Cannovation and Benuvia eliminate the regulatory and operational hurdles that have historically slowed controlled-substance innovation,” said Lisa Rich-Milan, CEO of Cannovation Clinical Research Partners. “This partnership represents a true end-to-end solution—uniting preclinical research, clinical execution, regulatory alignment, and GMP manufacturing under one coordinated framework.”

An Integrated Pathway from Discovery to Commercialization

The collaboration bridges what has traditionally been a fragmented landscape—where preclinical research, clinical trials, regulatory management, and GMP manufacturing were managed by separate vendors. Through this partnership, sponsors gain:

• Streamlined IND-to-trial transfer with unified regulatory oversight

• Accelerated timelines through reduced vendor friction and aligned compliance standards

• Access to global trial networks across North America, Europe, and Latin America

• DEA-licensed manufacturing for Schedule I–V substances including psilocybin, LSD, and DMT

• Comprehensive commercialization strategies to ensure faster, safer routes to patients

  
  

“By integrating Benuvia’s DEA-licensed GMP capabilities with Cannovation’s global clinical and regulatory network, we are redefining how complex therapeutics reach patients,” said Terry Novak, CEO of Benuvia. “This partnership provides the speed, compliance, and scalability pharmaceutical innovators need to succeed in today’s controlled-substance environment.”

Accelerating Innovation in Psychedelics, Cannabinoids, and Novel Therapeutics

With expanding research into psychedelic-based CNS treatments for depression, PTSD, and addiction, and a rapidly growing cannabinoid pharmaceutical market projected to exceed $430 billion globally by 2032, the timing of this partnership positions both companies at the forefront of a new era in medical science.

“This collaboration underscores our shared mission to improve global healthcare through the responsible development and commercialization of controlled-substance therapeutics,” added Lisa Rich-Milan. “Together, Cannovation and Benuvia are building a compliant, scalable, and globally accessible ecosystem for next-generation medicine.”